Back

Johnson & Johnson

Ticker: JNJ ISIN: US4781601046
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Market cap
$563.77B
P/E
27.14
Forward P/E
20.24
Profit margin
21.83%
Revenue growth QoQ
9.90%
Div. yield
2.21%
Beta
0.26
$266.35 -0.27%
Price as of 2026-09-10 · NYSE

Performance by timeframe

Rolling returns
1 Month +2.61%
6 Months +11.47%
1 Year +52.59%
5 Years +13.07% p.a.+84.73%
10 Years +11.52% p.a.+197.26%
Since inception +9.35% p.a.+832.13%
Calendar year returns
YTD +30.79%
2025 +47.48%
2024 -4.81%
2023 -8.58%
2022 +5.97%
2021 +11.44%

Key stats

Market cap
563.77B
P/E
27.14
Dividend yield
2.21%
Beta
0.26
52-week range
145.39 - 250.24
50-day MA
230.63
200-day MA
215.48
Section 1

Business overview

Company profile data from fundamentals.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 26.42%
ROA 8.42%
Profit margin 21.83%
Operating margin 27.41%
PEG ratio 3.04
Revenue/share TTM 40.02
Revenue TTM 96.36B
EBITDA 34.33B
Gross profit TTM 65.56B
Beta 0.26

Valuation

Trailing P/E 27.14
Forward P/E 20.24
P/B 6.94
P/S 5.85
EV/EBITDA 17.70
EV/Revenue 6.19
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 11.57
Quarterly earnings growth -52.90%
Revenue TTM 96.36B
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 2.21%
Dividend per share 5.2000
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 3.06
Short % of float 1.08%

Details

Instrument metadata and source update timestamps.

Symbol JNJ
Name Johnson & Johnson
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US4781601046
Country USA
Code + exchange JNJ.NYSE
Last price date 2026-06-17
Fundamentals updated 2026-06-18

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.